Merck withdraws MAA for asthma candidate

The European Medicines Agency (EMA) said Merck & Co. Inc. (NYSE:MRK) withdrew an MAA for Zenhale mometasone/formoterol inhalation aerosol as long-term maintenance to treat asthma in patients 12 years and older. According to the agency, the pharma said it would not be able to address requests from EMA's CHMP and provide additional data within the time frame allowed. The MAA was submitted on Aug. 3, 2009. ...